@itsanewmeemj's 'worst Mounjaro dose' claim, fact-checked

What did @itsanewmeemj actually say?

The creator is stepping down from 7.5 mg to 5 mg tirzepatide (Mounjaro) ahead of skin removal surgery, which is scheduled in under 30 days. They say appetite suppression is still strong at the lower dose and plan one final injection before going under the knife. They also mention ADHD symptoms feeling more noticeable during this period, though they clarify that is not why they take Mounjaro. On the question of staying on the drug long-term, they are refreshingly honest: "If I come off it and I'm absolutely ragin and I can't control myself, I'll go back on it." They frame tirzepatide as a tool for managing a relationship with food, not just a weight-loss shortcut. That framing, at least, is grounded in how the drug actually works.

Does the science back this up?

Largely, yes, though with important gaps the creator does not address. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 5 mg produced meaningful weight loss and appetite reduction, so the claim that "suppression's still high" at 5 mg is plausible. Appetite suppression does not drop off a cliff when you step down one dose level. However, there is no published guidance specifically on how to taper tirzepatide before elective surgery, and the creator presents their personal taper schedule as though it is settled protocol. It is not. On the ADHD observation, there is limited but emerging research suggesting GLP-1 receptor agonists may affect dopamine pathways relevant to ADHD (Himmerich et al., 2023, CNS Drugs), but this is early-stage data, not a clinical conclusion. The creator is noticing something real, but the mechanism is not well understood yet.

What did they get wrong (or right)?

They got the big picture right. Tirzepatide is a dual GIP and GLP-1 receptor agonist, and framing it as support for food-related behavioral issues rather than a magic fix reflects what the clinical evidence actually shows. Weight regain after stopping GLP-1 drugs is well-documented. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found that patients regained roughly two-thirds of their lost weight within a year of stopping semaglutide, and tirzepatide is likely similar. The creator intuitively understands this when they say they will restart if needed. What they get wrong, or at least incomplete, is the surgical timing piece. Most anesthesiologists now recommend stopping GLP-1 drugs at least one week before elective surgery due to gastroparesis risk and aspiration concerns under general anesthesia. The American Society of Anesthesiologists issued guidance on this in 2023. One injection timed a week before surgery may or may not clear that window depending on their exact schedule, and viewers should not assume their taper plan is safe for everyone.

What should you actually know?

If you are on a GLP-1 drug and planning surgery, do not take dosing or timing cues from social media, including this video. The ASA 2023 guidance recommends stopping weekly GLP-1 medications at least seven days before elective procedures. Gastroparesis, a slowing of stomach emptying that tirzepatide can cause, raises the risk of aspiration during anesthesia even if you have fasted. This is not a hypothetical risk. Your surgeon and anesthesiologist need to know you are on this class of drug, full stop. The creator's instinct to step down before surgery is sensible, but the specifics of how, when, and whether to restart are decisions that require a conversation with a medical team, not a TikTok update. On the question of long-term use, the data supports what the creator is saying: many people need to stay on tirzepatide to maintain results. That is a clinical reality, not a personal failing.

The ADHD comment deserves its own note

The creator mentions their ADHD symptoms felt more pronounced during this taper week, rating themselves "eight out of ten" on the ADHD scale. This is worth flagging because some users report cognitive and behavioral changes when adjusting GLP-1 doses, and a small body of research is starting to examine why. Drucker (2022, Cell Metabolism) identified GLP-1 receptors in areas of the brain involved in dopamine regulation, which could plausibly affect attention and impulse control. But this is mechanistic research, not clinical evidence that tirzepatide treats or worsens ADHD. The creator is not claiming it does, to their credit. They are just noting a personal observation. That is fair. What would not be fair is anyone watching this and concluding that Mounjaro is an ADHD treatment or that coming off it will tank your focus. The evidence does not support that leap.